EUVIMEDEUVIMED entdecken
Open Access

Liver-directed AAV gene therapy in mice corrects glycogen storage disease type IX γ2

Rebecca A Gibson iD, William R Jeck iD, Rebecca L Koch iD, Neha Jumani iD, Su Jin Choi iD, Deeksha Bali iD, Sarah P Young iD, Aravind Asokan iD, Jeong-A Lim iD, Priya S Kishnani iD

Science Advances · 2025

DOI: 10.1126/sciadv.ady6760 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2025. Verfasst von Rebecca A Gibson und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27705, USA. Hauptthemen laut MEDLINE: Genetic Therapy, Dependovirus, Liver, Genetic Vectors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NICHD NIH HHS, NIGMS NIH HHS, Eunice Kennedy Shriver National Institute of Child Health and Human Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glycogen storage disease (GSD) type IX γ2 is a rare inborn error of metabolism where a defect in glycogenolysis leads to the inability to break down glycogen in the liver. Patients with GSD IX γ2 develop hypoglycemia and advanced liver disease, placing them at risk for liver transplantation. This study evaluates the efficacy of liver-directed AAV gene therapy in a murine model of GSD IX γ2. Phkg2 −/− mice underwent treatment with AAV gene therapy (AAV9-LSP- mPhkg2 , 5 × 10 12 vg/kg, intravenous delivery) at ages 3 or 6 months and were treated for either 2 weeks, 3 months, or 12 months. Results demonstrated that AAV gene therapy reduced GSD IX γ2 disease burden across all primary end points. AAV gene therapy also persisted across the mouse lifespan and reduced preexisting liver fibrosis. This work provides preclinical data supporting AAV gene therapy as a definitive treatment for GSD IX γ2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TherapyDependovirusLiverGenetic VectorsGlycogen Storage DiseaseAnimalsMiceDisease Models, AnimalMice, KnockoutHumansMale

Autor:innen und Institutionen

  • Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27705, USA.
  • Division of Medical Genetics, Department of Pediatrics, Duke University Medical Center, Durham, NC 27705, USA.
  • Department of Pathology, Duke University Medical Center, Durham, NC 27705, USA.
  • Department of Surgery, Duke University Medical Center, Durham, NC 27705, USA.

ORCID-Profile: Rebecca A Gibson, William R Jeck, Rebecca L Koch, Neha Jumani, Su Jin Choi, Deeksha Bali, Sarah P Young, Aravind Asokan, Jeong-A Lim, Priya S Kishnani

Förderung

  • NICHD NIH HHS
  • NIGMS NIH HHS
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • Kriya Therapeutics

Zitieren

APA

Gibson, R. A., Jeck, W. R., Koch, R. L., Jumani, N., Choi, S. J., Bali, D., Young, S. P., Asokan, A., Lim, J. A., & Kishnani, P. S. (2025). Liver-directed AAV gene therapy in mice corrects glycogen storage disease type IX γ2. Science Advances. https://doi.org/10.1126/sciadv.ady6760

Vancouver

Gibson RA, Jeck WR, Koch RL, Jumani N, Choi SJ, Bali D, et al. Liver-directed AAV gene therapy in mice corrects glycogen storage disease type IX γ2. Science Advances. 2025. doi:10.1126/sciadv.ady6760

BibTeX
@article{Gibson2025,
  author = {Gibson, Rebecca A and Jeck, William R and Koch, Rebecca L and Jumani, Neha and Choi, Su Jin and Bali, Deeksha and Young, Sarah P and Asokan, Aravind and Lim, Jeong-A and Kishnani, Priya S},
  title = {Liver-directed AAV gene therapy in mice corrects glycogen storage disease type IX γ2},
  journal = {Science Advances},
  year = {2025},
  doi = {10.1126/sciadv.ady6760}
}
Kostenlos starten →